A Phase II Study of 2-Methoxyestradiol (2ME2) NanoCrystal(®) Dispersion (NCD) in Patients with Taxane-Refractory, Metastatic Castrate-Resistant Prostate Cancer (CRPC)

PURPOSE: 2ME2 (Panzem(®)) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC. EXPERIMENTAL DE...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Harrison, Michael R., Hahn, Noah M., Pili, Roberto, Oh, William K., Hammers, Hans, Sweeney, Christopher, Kim, KyungMann, Perlman, Scott, Arnott, Jamie, Sidor, Carolyn, Wilding, George, Liu, Glenn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3042040/
https://ncbi.nlm.nih.gov/pubmed/20499131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9455-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia